JP5232472B2 - 向上された生体利用効率を備えるプランルカスト固体分散体組成物およびその固体分散体の製造方法 - Google Patents

向上された生体利用効率を備えるプランルカスト固体分散体組成物およびその固体分散体の製造方法 Download PDF

Info

Publication number
JP5232472B2
JP5232472B2 JP2007540251A JP2007540251A JP5232472B2 JP 5232472 B2 JP5232472 B2 JP 5232472B2 JP 2007540251 A JP2007540251 A JP 2007540251A JP 2007540251 A JP2007540251 A JP 2007540251A JP 5232472 B2 JP5232472 B2 JP 5232472B2
Authority
JP
Japan
Prior art keywords
pranlukast
solid dispersion
polymer
present
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2007540251A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008519067A5 (enExample
JP2008519067A (ja
Inventor
ジュン−ギョ オ，
ヨン ホ オ，
ホ チョル シン，
チ ソン ジョン，
キ−アン オム，
ドン ソン ミン，
ナム ギュ イ，
ジュ ヨン イ，
グアン−ジン イム，
テ コン キム，
ジョン テ キム，
ウ ジェ チャン，
ドン チョル シン，
ウン−シク キム，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SK Chemicals Co Ltd
Original Assignee
SK Chemicals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36319405&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5232472(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by SK Chemicals Co Ltd filed Critical SK Chemicals Co Ltd
Publication of JP2008519067A publication Critical patent/JP2008519067A/ja
Publication of JP2008519067A5 publication Critical patent/JP2008519067A5/ja
Application granted granted Critical
Publication of JP5232472B2 publication Critical patent/JP5232472B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2007540251A 2004-11-04 2005-11-03 向上された生体利用効率を備えるプランルカスト固体分散体組成物およびその固体分散体の製造方法 Expired - Fee Related JP5232472B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2004-0089455 2004-11-04
KR1020040089455A KR101086254B1 (ko) 2004-11-04 2004-11-04 생체이용률이 개선된 프란루카스트 고체분산체 조성물 및그 고체분산체의 제조방법
PCT/KR2005/003686 WO2006049433A1 (en) 2004-11-04 2005-11-03 Solid dispersion composition of pranlukast with improved bioavailibility and the method of preparing the solid dispersion

Publications (3)

Publication Number Publication Date
JP2008519067A JP2008519067A (ja) 2008-06-05
JP2008519067A5 JP2008519067A5 (enExample) 2008-12-04
JP5232472B2 true JP5232472B2 (ja) 2013-07-10

Family

ID=36319405

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007540251A Expired - Fee Related JP5232472B2 (ja) 2004-11-04 2005-11-03 向上された生体利用効率を備えるプランルカスト固体分散体組成物およびその固体分散体の製造方法

Country Status (6)

Country Link
JP (1) JP5232472B2 (enExample)
KR (1) KR101086254B1 (enExample)
AR (1) AR051758A1 (enExample)
MX (1) MX2007005427A (enExample)
TW (1) TWI380829B (enExample)
WO (1) WO2006049433A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101233235B1 (ko) * 2005-08-26 2013-02-15 에스케이케미칼주식회사 초기 용출율이 개선된 프란루카스트 고체분산체의 약제학적조성물 및 그의 제조방법
EP4008314A3 (en) * 2007-08-21 2022-11-09 Board of Regents, The University of Texas System Thermo-kinetic mixing for pharmaceutical applications
CA3076115C (en) 2007-08-21 2022-06-28 Board Of Regents, The University Of Texas System Thermo-kinetic mixing for pharmaceutical applications
EP2140861A1 (en) * 2008-06-30 2010-01-06 Abbott GmbH & Co. KG Pharmaceutical dosage form comprising polymeric carrier composition
GB201103837D0 (en) * 2011-03-07 2011-04-20 Oxagen Ltd Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid
KR101381881B1 (ko) * 2012-03-12 2014-04-04 충남대학교산학협력단 용해도 및 용출율이 개선된 프란루카스트 나노 고체 분산체의 제조방법
KR101446129B1 (ko) * 2012-10-10 2014-10-06 조선대학교산학협력단 프란루카스트-함유 고형 제제의 제조방법
KR102191562B1 (ko) * 2012-11-07 2020-12-15 에스케이바이오팜 주식회사 난용성 약물의 고체분산체 및 이의 제조방법
KR102363727B1 (ko) 2015-06-01 2022-02-16 삼아제약 주식회사 생체이용률이 개선된 프란루카스트 함유 고형 제제의 조성물 및 그 제조방법
CA3099901C (en) 2018-07-13 2024-03-19 Council Of Scientific & Industrial Research Solid dispersion comprising an anticancer compound for improved solubility and efficacy
KR20240164596A (ko) 2023-05-09 2024-11-20 삼아제약 주식회사 복약편의성이 증진된 프란루카스트 함유 약제학적 조성물
KR102840220B1 (ko) * 2023-07-18 2025-07-31 삼아제약 주식회사 프란루카스트 함유 약제학적 조성물의 제조방법 및 상기 제조방법에 의해 제조된 약제학적 조성물
KR20250052834A (ko) 2023-10-12 2025-04-21 주식회사 다산제약 프란루카스트의 생체이용률이 개선된 약제학적 조성물 및 그 제조방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19509807A1 (de) * 1995-03-21 1996-09-26 Basf Ag Verfahren zur Herstellung von Wirkstoffzubereitungen in Form einer festen Lösung des Wirkstoffs in einer Polymermatrix sowie mit diesem Verfahren hergestellte Wirkstoffzubereitungen
DE69625813T2 (de) * 1995-06-12 2003-09-04 Ono Pharmaceutical Co. Ltd., Osaka Pranlukast enthaltende granula, verfahren zur herstellung der granula und verfahren zur verminderung des zusammenbackens von pranlukast
US5858509A (en) * 1996-11-15 1999-01-12 Digital Equipment Corporation Attenuating vibrations in a mounting shelf for multiple disk drives
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
KR100381834B1 (ko) * 2000-05-20 2003-04-26 이상득 용출성이 개선된 프란루카스트 고체분산체 조성물 및 그제조 방법
UA80393C2 (uk) 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці

Also Published As

Publication number Publication date
WO2006049433A1 (en) 2006-05-11
TW200621307A (en) 2006-07-01
KR101086254B1 (ko) 2011-11-24
AR051758A1 (es) 2007-02-07
KR20060040211A (ko) 2006-05-10
JP2008519067A (ja) 2008-06-05
MX2007005427A (es) 2012-10-02
TWI380829B (zh) 2013-01-01

Similar Documents

Publication Publication Date Title
TWI389691B (zh) 可口服且具有活性成分快速釋出之固態醫藥劑型
KR101159617B1 (ko) 구강내 속붕해성 정제
EP2886109B1 (en) Medicament-containing hollow particle
JP5232472B2 (ja) 向上された生体利用効率を備えるプランルカスト固体分散体組成物およびその固体分散体の製造方法
JP2001511156A (ja) 高いバイオアベイラビリティーを有するフェノフィブレート医薬組成物及びそれを調製するための方法
JP2001527044A (ja) イトラコナゾール（ｉｔｒａｃｏｎａｚｏｌｅ）経口用製剤及びその製造方法
JP2003518038A (ja) 流動床噴霧乾燥によるナノ粒子製造方法
CN100560067C (zh) 盐酸决奈达隆口服药物组合物及其制备方法
JP2001515029A (ja) 粒状分散形態の固形医薬剤形
JP2009524646A (ja) 多孔性微粒子の製造方法
JP3967924B2 (ja) 溶出性の改善されたプランルカスト固体分散系及びその製造方法
TWI389915B (zh) 肝適能之穩定化固態分散及其製備方法
CN106619520A (zh) 一种右兰索拉唑钠的干混悬剂及其制备方法
CA2253769C (en) Pharmaceutical compositions comprising fenofibrate
WO2006087919A1 (ja) 難水溶性物質含有微細化組成物
CN108012526A (zh) 具有改进的生物利用度的含普仑司特固体制剂的组合物及其制备方法
CN109988104A (zh) 山奈酚与异烟酰胺共晶物及制备方法和其药物组合物与用途
JP5297194B2 (ja) 初期溶解率が改善されたプランルカスト固体分散体の薬剤学的組成物およびその製造方法
CN113599366B (zh) 一种富马酸替诺福韦二吡呋酯颗粒及其制备方法
JPH107558A (ja) 溶解性改善製剤
TWI356711B (en) Saquinavir mesylate oral dosage form
WO2001085135A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING ITRACONAZOLE WITH GASTRIC pH-INDEPENDENTLY IMPROVED SOLUBILITY AND PREPARATION METHOD THEREOF
CN107281148A (zh) 一种固体分散体及其固体制剂的制备方法
CN117562900A (zh) 具有明显临床优势的阿哌沙班新制剂组合物及其制备方法
JPH01168619A (ja) 新規な酢酸クロルマジノン固形製剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081015

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20081015

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111220

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120319

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120327

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120420

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120509

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120518

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120525

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120620

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130305

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130325

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20160329

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees